# US 2024/0083850 A1 · Novel lappaconitine derivative and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0083850 A1
- Document ID: US20240083850A1
- Status: Published application
- Kind: A1
- Application number: 17/905,797
- Filed: 2021-03-05
- Published: 2024-03-14
- Earliest claimed: 2020-03-09
- Assignees: Qgenetics Co., Ltd.
- Applicants: Qgenetics Co., Ltd.
- Inventors: Mun Seog CHANG; Tae Hee LEE; Ha Young KIM; Jung Bin MIN
- Web page: https://patentgrep.com/patent/US20240083850A1

## CPC

- A61P 19/00: Drugs for skeletal disorders
- C07D 223/32: containing carbocyclic rings other than six-membered
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/4825: {Proteins, e.g. gelatin (gelatin capsule shells with substantial amounts of other macromolecular substances A61K9/4816)}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention pertains to a novel lappaconitine derivative, a method for producing same, and a pharmaceutical use thereof using osteogenesis-promoting activity. The lappaconitine derivative induces the differentiation of stem cells into osteoblasts, increases bone mineral density when administered to animal models of osteoporosis, and induces bone formation in animal models of bone fracture, and thus can be advantageously used for preventing, ameliorating, or treating bone-related diseases such as osteoporosis, as well as treating non-disease fractures caused by physical trauma.

## Claims

### Claim 1

A compound represented by the following Formula 1, and a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof:
wherein R1 and R2 are each independently selected from the group consisting of hydrogen, a C1-C6 alkyl, a thioalkyl, an arylalkyl, a hydroxyalkyl, a dihydroxyalkyl, a hydroxy alkylarylalkyl, a dihydroxyalkylarylalkyl, an alkoxyalkyl, an acyloxyalkyl, an aminoalkyl, an alkylaminoalkyl, an alkoxycarbonylaminoalkyl, an acylaminoalkyl, an arylsulfoneamidoalkyl, an allyl, a dihydroxyalkylallyl, a dioxolanylallyl, a caralkoxyalkyl, methyl, ethyl, isopropyl, t-butyl, and phenyl.

### Claim 2

A pharmaceutical composition for preventing or treating a bone-related disease, comprising a compound represented by the following Formula 1, and a stereoisomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein R1 and R2 are each independently selected from the group consisting of hydrogen, a C1-C6 alkyl, a thioalkyl, an arylalkyl, a hydroxyalkyl, a dihydroxyalkyl, a hydroxy alkylarylalkyl, a dihydroxyalkylarylalkyl, an alkoxyalkyl, an acyloxyalkyl, an aminoalkyl, an alkylaminoalkyl, an alkoxycarbonylaminoalkyl, an acylaminoalkyl, an arylsulfoneamidoalkyl, an allyl, a dihydroxyalkylallyl, a dioxolanylallyl, a caralkoxyalkyl, methyl, ethyl, isopropyl, t-butyl, and phenyl.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the bone-related disease is selected from the group consisting of osteoporosis, bone fractures, rheumatoid arthritis, periodontitis, osteomalacia, osteopenia, bone atrophy, osteoarthritis, bone defects, osteolysis, and osteonecrosis.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the compound represented by Formula 1 promotes the differentiation of stem cells into osteoblasts.

### Claim 5 (depends on 2)

The pharmaceutical composition of claim 2, wherein the compound represented by Formula 1 increases the expression of an osteogenic marker selected from the group consisting of runt-related transcription factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2), and osteocalcin.

### Claim 6 (depends on 1)

A food composition for preventing or ameliorating a bone-related disease, comprising the compound of claim 1 as an active ingredient.

### Claim 7 (depends on 6)

The food composition of claim 6, wherein the compound represented by Formula 1 promotes the differentiation of stem cells into osteoblasts.

### Claim 8 (depends on 1)

A method of synthesizing the compound of claim 1, comprising:
(a) allowing lappaconitine to react with an oxidizing agent; and
(b) allowing the reaction product of (a) to react with an organic solvent in the presence of a base.

### Claim 9 (depends on 8)

The method of claim 8, wherein the oxidizing agent of (a) is selected from the group consisting of phenyliodine diacetate (PhI(OAc)2, lead (II) acetate (Pb(CH3CO2)2), lead (II) acetate (Pb(CH3CO2)4), ozone, and HIO4.

### Claim 10 (depends on 8)

The method of claim 8, wherein the base of (b) is selected from the group consisting of sodium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, and potassium hydroxide.

### Claim 11 (depends on 8)

The method of claim 8, wherein the organic solvent of (b) is an aliphatic alcohol or an alkoxy alcohol.

### Claim 12 (depends on 2)

A method of treating a bone-related disease, comprising:
administering the pharmaceutical composition of claim 2 to a subject in need of treatment.
